Abstract:The 2019-2020 winter was marked by the emergence of a new coronavirus (SARS-CoV-2) related disease (COVID-19), which started in Wuhan, China. Its high human-to-human transmission ability led to a worldwide spread within few weeks and has caused substantial human loss. Mechanical antiviral control approach, drug repositioning, and use of COVID-19 convalescent plasmas (CPs) were the first line strategies utilized to mitigate the viral spread, yet insufficient. The urgent need to contain this deadly pandemic has led searchers and pharmaceutical companies to develop vaccines. However, not all vaccines manufactured are safe. Besides, an alternative and effective treatment option for such an infectious disease would include pure anti-viral neutralizing monoclonal antibodies (NmAbs), which can block the virus at specific molecular targets from entering cells by inhibiting virus-cell structural complex formation, with more safety and efficiency than the CP. Indeed, there is a lot of molecular evidence about the protector effect and the use of molecular feature-based NmAbs as promising therapeutics to contain COVID-19. Thus, from the scientific publication database screening, we here retrieved antibody-related papers and summarized the repertory of characterized NmAbs against SARS-CoV-2, their molecular neutralization mechanisms, and their immunotherapeutic pros and cons. About 500 anti-SARS-CoV-2 NmAbs, characterized through competitive binding assays and neutralization efficacy, were reported at the writing time (January 2021). All NmAbs bind respectively to SARS-CoV-2 S and exhibit high molecular neutralizing effects against wild-type and/or pseudotyped virus. Overall, we defined six NmAb groups blocking SARS-CoV-2 through different molecular neutralization mechanisms, from which five potential neutralization sites on SARS-CoV-2 S protein are described. Therefore, more efforts are needed to develop NmAbs-based cocktails to mitigate COVID-19.

SARS-CoV-2 neutralizing antibody development strategies

The development of neutralizing antibodies against SARS-CoV-2 and their common features

Neutralizing Monoclonal Antibodies Present New Prospects to Treat SARS-CoV-2 Infections

Monoclonal neutralizing antibodies against SARS-COV-2 S protein

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses

Potent Molecular Feature-based Neutralizing Monoclonal Antibodies As Promising Therapeutics Against SARS-CoV-2 Infection

COVID-19-neutralizing antibodies predict disease severity and survival

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses

Neutralization of SARS-CoV-2 Infection by Antibodies Targeting Diverse Epitopes

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

[Sars-Cov-2 Neutralizing Monoclonal Antibodies and Nanobodies: a Review].

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Development and characterization of SARS-CoV-2 variant-neutralizing monoclonal antibodies

The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection